These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 9744444)
1. The mean ventricular fibrillation cycle length: a potentially useful parameter for programming implantable cardioverter defibrillators. Li H; Easley A; Windle J; Samoil D; Barrington W Pacing Clin Electrophysiol; 1998 Sep; 21(9):1789-94. PubMed ID: 9744444 [TBL] [Abstract][Full Text] [Related]
2. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK; J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248 [TBL] [Abstract][Full Text] [Related]
3. Programming of implantable cardioverter-defibrillators on the basis of the upper limit of vulnerability. Swerdlow CD; Peter CT; Kass RM; Gang ES; Mandel WJ; Hwang C; Martin DJ; Chen PS Circulation; 1997 Mar; 95(6):1497-504. PubMed ID: 9118518 [TBL] [Abstract][Full Text] [Related]
4. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies. Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243 [TBL] [Abstract][Full Text] [Related]
15. Results of ENHANCED Implantable Cardioverter Defibrillator Programming to Reduce Therapies and Improve Quality of Life (from the ENHANCED-ICD Study). Mastenbroek MH; Pedersen SS; van der Tweel I; Doevendans PA; Meine M Am J Cardiol; 2016 Feb; 117(4):596-604. PubMed ID: 26732419 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of high-rate cutoff and long detection interval ICD programming in secondary prevention patients. Hayashi Y; Takagi M; Kakihara J; Sakamoto S; Doi A; Sugioka K; Hanatani A; Yoshiyama M Heart Vessels; 2017 Feb; 32(2):175-185. PubMed ID: 27259484 [TBL] [Abstract][Full Text] [Related]
17. Ventricular tachyarrhythmias in patients receiving an implantable cardioverter-defibrillator for primary versus secondary prophylaxis indications. Manuchehry A; Agusala K; Montevecchi M; Kadish A; Passman R Pacing Clin Electrophysiol; 2011 May; 34(5):571-6. PubMed ID: 21208242 [TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up in patients with arrhythmogenic right ventricular cardiomyopathy. Li CH; Lin YJ; Huang JL; Wu TJ; Cheng CC; Lin WS; Tuan TC; Chang SL; Lo LW; Hu YF; Chao TF; Chung FP; Tsai CF; Tsao HM; Chen SA J Cardiovasc Electrophysiol; 2012 Jul; 23(7):750-6. PubMed ID: 22353378 [TBL] [Abstract][Full Text] [Related]
19. Clinical application of the fibrillation number in patients with an implantable cardioverter defibrillator. Hwang M; Lee H; Lee YS; Chung S; Choi SH; Shim EB; Pak HN Prog Biophys Mol Biol; 2014 Sep; 116(1):33-9. PubMed ID: 25236363 [TBL] [Abstract][Full Text] [Related]
20. Implantable Cardioverter Defibrillator Programming Characteristics, Shocked Rhythms, and Survival Among Patients Under Thirty Years of Age. Chang PM; Powell BD; Jones PW; Carter N; Hayes DL; Saxon LA J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1183-1190. PubMed ID: 27334356 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]